HB 1169 South Dakota House · 2026 Regular Session

classify medetomidine as a Schedule III controlled substance and establish permissible uses.

HB 1169 classifies medetomidine - a drug used in veterinary medicine - as a state-controlled substance under Schedule III, effective January 1, 2026. This bill directly affects veterinarians, animal drug manufacturers, and pharmacists who handle medetomidine for animal use. The key provision exempts specific veterinary applications, including federally approved animal drugs (under 21 U.S.C. § 360b) and uses permitted by federal law, ensuring continued access for animal care while imposing state-level controls on other uses.

Bill status signed all 5 stages cleared

Introduction

Jan 2026

Committee Review

Feb 2026

House Passage

Feb 2026

Senate Passage

Mar 2026

Signed into Law

Mar 2026

Introduced Jan 28, 2026 Signed Mar 9, 2026

Maddy AI version diff · 1 comparison

What changed between versions

Introduced → Enrolled · 4 edits · Mar 1, 2026

MODERATE

This bill enrolls HB 1169, which classifies medetomidine as a Schedule III controlled substance in South Dakota while establishing specific exceptions for veterinary use. The text transitions from a browser error page to the final enrolled version of the legislation, including signature blocks and filing information. This change formalizes the bill into law, making it enforceable and establishing clear legal guidelines for medetomidine use in veterinary medicine.

Scope change

The bill's scope remains focused on medetomidine classification and veterinary use exceptions, but the enrolled version adds official legislative formatting, signature blocks, and filing details required for the bill to become effective law.

TIMELINE

Added effective date references (January 1, 2026) and legislative session information (101st Legislative Session) to establish when the law takes effect.

ENFORCEMENT

Added signature blocks for House and Senate leadership, Governor approval, and Secretary of State filing to complete the legal enactment process.

TECHNICAL

Removed browser compatibility warnings and website loading messages that were present in the initial version but are not part of the actual legislation.

DEFINITION

Added detailed statutory language defining medetomidine as Schedule III with five specific exceptions for veterinary use, including references to federal regulations (21 U.S.C. § 360b).

Floor votes

How they voted

This bill passed the Senate by voice vote (no roll call recorded).

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Mar 9, 2026

Signed into law

Signed by the Governor on 2026-03-09 H.J. 534

executive

Mar 3, 2026

Upper · Passed

Signed by the President S.J. 448

upper

Mar 2, 2026

Upper · Passed

Signed by the Speaker H.J. 477

upper

Feb 26, 2026

Upper · Passed

Senate Do Pass , Passed, YEAS 32, NAYS 0 S.J. 412

upper

Feb 25, 2026

Upper · Passed

Certified uncontested, placed on consent , Passed, S.J. 21

upper

Feb 25, 2026

Upper · Passed

Health and Human Services Do Pass , Passed, YEAS 7, NAYS 0 S.J. 21

upper

Feb 12, 2026

Introduced

First read in Senate and referred to Senate Health and Human Services S.J. 260

upper

Feb 11, 2026

Lower · Passed

House of Representatives Do Pass , Passed, YEAS 63, NAYS 3 H.J. 295

lower

Feb 10, 2026

Lower · Passed

Certified uncontested, placed on consent , Passed,

lower

Feb 10, 2026

Lower · Passed

Health and Human Services Do Pass , Passed, YEAS 11, NAYS 0

lower

Jan 28, 2026

Introduced

First read in House and referred to House Health and Human Services H.J. 163

lower

10 primary · 0 co-sponsors